(37) Implant Survival in Tissue-engineered Mandibular Reconstruction

Abstract:

Purpose: The purpose of this article is to evaluate the early outcomes (average 25 months of follow-up) of dental implants placed in bone generated with tissue engineering techniques, specifically recombinant human bone morphogenic protein-2 (rhBMP-2), allogeneic bone particulate, and bone marrow aspirate concentrate (BMAC).

Methods: We retrospectively evaluated 12 patients, all of whom underwent segmental mandibular resection and reconstruction with a combination of BMAC, rhBMP-2, and allogeneic bone. Collected data points included the patient’s age, gender, medical and social histories, implant site and placement date, resection/reconstruction date, final prosthesis, pathology resected, and follow-up dates. Implant success was defined as clinical osseointegration (immobility), absence of peri-implant radiolucency, and absence of infection.

Results: 12 patients met inclusion criteria with a total 46 implants. The overall implant survival rate was 91.3%. There were 4 implant failures occurring in two patients: 1 failure in Patient 3 and 3 failures in Patient 8. Neither patient had any existing medical comorbidities or social history known to increase the risk for implant failure. The average implant placement occurred 11.6 months after mandibular reconstruction.

Conclusion: Preliminary findings of implant placement in bone generated with tissue engineering techniques has shown to be another predictable alternative for orofacial rehabilitation.